Alpha-1 Antitrypsin Deficiency

1. Clinical Overview

Summary

Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic disorder caused by mutations in the SERPINA1 gene located on chromosome 14q32.13, resulting in reduced circulating levels or dysfunctional alpha-1 antitrypsin (AAT) protein. [1] AAT is the principal serine protease inhibitor (serpin) in human plasma, providing more than 90% of anti-neutrophil elastase capacity in the lower respiratory tract. [2] The prototypic manifestation is early-onset panacinar emphysema, characteristically affecting the lung bases, which occurs due to unopposed proteolytic destruction of lung parenchyma by neutrophil elastase. [3]

The condition exhibits remarkable phenotypic heterogeneity—the same Pi*ZZ genotype produces severe emphysema in some individuals while others remain asymptomatic into old age. This variability reflects complex gene-environment interactions, with cigarette smoking being the most powerful disease modifier, accelerating lung function decline by 3-5 fold. [4] Importantly, the Z mutation causes not only deficiency but also toxic gain-of-function through intrahepatic polymerisation, leading to liver disease that can manifest from neonatal cholestasis to adult-onset cirrhosis and hepatocellular carcinoma. [5]

AATD remains the most commonly recognised genetic cause of both COPD and liver disease in adults. [6] Despite affecting an estimated 3.4 million individuals worldwide with severe deficiency, the condition is grossly underdiagnosed—over 90% of affected individuals remain unidentified. [7] International guidelines from the WHO, ATS, and ERS recommend one-time testing of all patients with COPD, yet testing rates remain below 10% in most countries. [1] Early diagnosis enables targeted interventions including absolute smoking avoidance, family cascade screening, and consideration of augmentation therapy, potentially transforming the natural history from premature death to near-normal life expectancy in never-smokers.

Key Facts

Clinical Pearls

The "Young and Basal" Pattern: Classic AATD-related emphysema presents in patients aged 35-50 (compared to 60+ in smoking-related COPD), affects the lung bases rather than apices, and may occur in non-smokers or light smokers. When emphysema doesn't fit the typical centrilobular upper-lobe pattern, AATD must be excluded. [3]

The Protein Trafficking Defect: The Z mutation doesn't just reduce AAT levels—it causes the protein to misfold and polymerise within hepatocyte endoplasmic reticulum. This creates a "toxic gain-of-function" where retained polymers cause liver injury while the lung suffers from deficiency. Null alleles cause severe lung disease but no liver disease because there is no protein to accumulate. [5]

The 90% Rule: More than 90% of individuals with severe AATD remain undiagnosed despite guidelines recommending testing. This represents one of medicine's most significant diagnostic gaps. A single serum AAT level with reflex genotyping can diagnose a lifelong condition—yet it is rarely performed. [7]

The Smoking Multiplier: Smoking accelerates FEV1 decline by 3-5 times in PiZZ individuals. A never-smoker with PiZZ may have near-normal life expectancy; a smoker with the same genotype has a mean survival of only 50-55 years. No other single intervention has comparable impact. [4]

Why This Matters Clinically

AATD exemplifies the intersection of genetics, environment, and preventable disease. Early identification enables:

1. Absolute smoking avoidance/cessation — transforms prognosis from fatal disease to near-normal life expectancy
2. Family cascade screening — identifies at-risk relatives before disease onset
3. Augmentation therapy consideration — may slow emphysema progression in eligible patients
4. Liver surveillance — enables early detection of cirrhosis and hepatocellular carcinoma screening
5. Occupational counselling — avoiding dust, fumes, and respiratory irritants
6. Transplant planning — liver transplantation is curative (replaces source of AAT)

The diagnosis is frequently missed because physicians don't consider it. Every COPD diagnosis should prompt a single AAT level with reflex genotyping—a simple test that can change the trajectory of a patient's life and their family members.

---

2. Epidemiology

Global Prevalence and Distribution

AATD demonstrates marked geographic variation reflecting founder effects and population genetics. The Z allele originated in Northern Europe approximately 4,000-5,000 years ago and spread through Viking migrations. [7]

Global Burden Estimates [7]:

• Severe deficiency (Pi*ZZ equivalent): 3.4 million individuals worldwide
• Pi*SZ compound heterozygotes: 1.5 million individuals
• Pi*MZ carriers: 116 million individuals globally
• United States: Approximately 100,000 with severe deficiency; fewer than 10% diagnosed

Incidence Patterns

The incidence of symptomatic AATD is influenced by both genetic prevalence and environmental modifiers:

Demographics and Presentation Patterns

Age at Presentation:

Sex Distribution:

• Genetic inheritance is equal between sexes
• Historical male predominance in symptomatic presentation reflected higher smoking rates
• Increasing female presentation as smoking patterns changed
• Liver disease shows less sex differential than lung disease

Underdiagnosis and Diagnostic Delay

The underdiagnosis of AATD represents one of medicine's most significant gaps [8]:

Barriers to Diagnosis:

• Low physician awareness and index of suspicion
• Assumption that all COPD is smoking-related
• Perception that diagnosis doesn't change management
• Cost and access to testing (though relatively inexpensive)
• Failure to recognise atypical patterns (young age, basal emphysema, non-smokers)

---

3. Genetics and Molecular Biology

SERPINA1 Gene Structure

The SERPINA1 gene (previously known as PI gene) is located on chromosome 14q32.13 within a cluster of serine protease inhibitor genes. [1]

Gene Characteristics:

• Size: Approximately 12.2 kilobases
• Exons: 7 coding exons (exons Ia, Ib, Ic non-coding; exons II-V coding)
• Protein product: 394 amino acid mature protein (52 kDa glycoprotein)
• Primary synthesis site: Hepatocytes (80-90% of circulating AAT)
• Alternative synthesis: Monocytes, macrophages, neutrophils, bronchial epithelium
• Plasma half-life: 4.5-5.5 days
• Normal plasma concentration: 1.5-3.5 g/L (20-48 μM)

Allele Nomenclature and Classification

AATD alleles are classified using the "Pi" (protease inhibitor) nomenclature system based on isoelectric focusing migration patterns [2]:

Normal Alleles:

Deficiency Alleles:

Null (Q0) Alleles:

Clinical Note: Null alleles cause severe lung disease but NO liver disease because no protein is produced to accumulate in hepatocytes. This distinguishes them from Z alleles where liver disease risk exists. [5]

Genotype-Phenotype Correlations

Common Genotypes and Expected Outcomes [1,2]:

Molecular Pathology of the Z Mutation

The Pi*Z mutation (Glu342Lys) is the paradigm for understanding serpinopathies. [5,11]

Structural Biology:

1. Normal AAT folding:

   • AAT is a metastable protein with a reactive centre loop (RCL) that acts as "bait" for elastase
   • Upon elastase binding, the RCL inserts into beta-sheet A, irreversibly trapping the protease
   • This "spring-loaded mousetrap" mechanism inactivates elastase

2. Z mutation effect:

   • Glutamate→Lysine at position 342 is at the base of the reactive centre loop
   • Disrupts the "breach" region where the RCL joins the main body
   • Creates thermodynamic instability and a tendency to spontaneous polymerisation

3. Polymerisation mechanism:

   • The RCL of one Z molecule inserts into beta-sheet A of another
   • Creates long, ordered polymers visible as inclusions in hepatocytes
   • These are the periodic acid-Schiff (PAS)-positive, diastase-resistant globules on histology
   • Polymer formation is temperature-dependent and accelerated by inflammation

Consequences of Polymerisation:

---

4. Pathophysiology

The Protease-Antiprotease Balance

The "protease-antiprotease hypothesis" proposed by Laurell and Eriksson in 1963 remains the foundation for understanding AATD-related lung disease. [12]

Normal Lung Protection:

NEUTROPHIL ELASTASE (NE)
        |
   ALVEOLAR ATTACK
        |
        ↓
┌─────────────────────────────────────────┐
│       ALPHA-1 ANTITRYPSIN (AAT)         │
│   Inhibits NE with 1:1 stoichiometry    │
│   Main protector of alveolar walls      │
│   Concentration in lung = 10% of serum  │
└─────────────────────────────────────────┘
        |
   PROTECTION MAINTAINED
        |
        ↓
   ALVEOLAR INTEGRITY PRESERVED

AATD: Disrupted Balance:

NEUTROPHIL ELASTASE (Normal/Increased)
        |
   ALVEOLAR ATTACK
        |
        ↓
┌─────────────────────────────────────────┐
│   DEFICIENT AAT (Pi*ZZ: 10-15%)         │
│   Threshold for protection: ~35% normal │
│   Pi*ZZ patients below protective level │
└─────────────────────────────────────────┘
        |
   UNOPPOSED ELASTOLYSIS
        |
        ↓
┌─────────────────────────────────────────┐
│     DESTRUCTION OF LUNG TISSUE          │
│  - Elastin degradation                  │
│  - Loss of alveolar walls               │
│  - Panacinar emphysema                  │
│  - Basilar predominance                 │
└─────────────────────────────────────────┘

Mechanism of Lung Injury

Step-by-Step Pathogenesis [3,11]:

Step 1: Neutrophil Recruitment

• Normal lung turnover recruits neutrophils (10⁹ daily transit through lungs)
• Smoking increases neutrophil influx 3-5 fold
• Infections and exacerbations cause neutrophil "storms"
• Resident alveolar macrophages also release neutrophil chemotactic factors

Step 2: Elastase Release

• Activated neutrophils degranulate, releasing neutrophil elastase (NE)
• NE is stored in azurophilic granules at very high concentrations
• Other proteases released: proteinase 3, cathepsin G
• Matrix metalloproteinases (MMPs) also contribute

Step 3: Insufficient Inhibition

• AAT is the primary inhibitor of NE in the lower respiratory tract
• Secretory leukoproteinase inhibitor (SLPI) provides backup but is insufficient
• In Pi*ZZ: AAT levels 10-15% of normal
• Protective threshold approximately 35% (11 μM) — Pi*ZZ patients below this

Step 4: Tissue Destruction

• Unopposed NE degrades elastin, the main structural protein of alveolar walls
• Collagen and proteoglycans also degraded
• Alveolar attachments to bronchioles disrupted
• Progressive loss of elastic recoil

Step 5: Emphysema Pattern

• Panacinar emphysema: entire acinus destroyed (vs. centrilobular in smoking)
• Basilar predominance: gravity-dependent neutrophil settling
• Early bullae formation
• Progressive hyperinflation

Amplification Factors

Cigarette Smoking Effect [4]:

Oxidative Stress:

• AAT contains a methionine residue (Met358) in the reactive centre loop
• Oxidation of Met358 inactivates AAT (reduces anti-NE activity by > 2000-fold)
• Sources of oxidants: cigarette smoke, activated neutrophils, air pollution
• Even in Pi*MM individuals, smokers' AAT is partially oxidatively inactivated

Hepatic Pathophysiology

The liver disease of AATD is mechanistically distinct from the lung disease—it results from toxic accumulation rather than deficiency. [5,13]

Mechanism of Liver Injury:

Z-AAT PROTEIN SYNTHESIS
        |
        ↓
┌─────────────────────────────────────────┐
│    MISFOLDING IN ENDOPLASMIC RETICULUM  │
│  Glu342Lys mutation disrupts structure  │
│  Protein fails quality control          │
└─────────────────────────────────────────┘
        |
        ↓
┌─────────────────────────────────────────┐
│    POLYMERISATION                       │
│  Loop-sheet polymerisation              │
│  Forms ordered protein aggregates       │
│  PAS-positive, diastase-resistant       │
└─────────────────────────────────────────┘
        |
        ↓
┌─────────────────────────────────────────┐
│    RETENTION AND ACCUMULATION           │
│  ER retention → ER stress               │
│  Unfolded protein response activation   │
│  Autophagy activation                   │
└─────────────────────────────────────────┘
        |
        ↓
┌─────────────────────────────────────────┐
│    HEPATOCYTE INJURY                    │
│  - Overwhelmed autophagy                │
│  - Mitochondrial dysfunction            │
│  - Apoptosis and necrosis              │
│  - Chronic inflammation                 │
└─────────────────────────────────────────┘
        |
        ↓
┌─────────────────────────────────────────┐
│    FIBROSIS AND CIRRHOSIS               │
│  Stellate cell activation               │
│  Progressive fibrosis                   │
│  Regenerative nodules → HCC risk        │
└─────────────────────────────────────────┘

Key Distinction: Null alleles produce NO AAT protein, causing severe lung disease but NO liver disease because there are no Z polymers to accumulate.

The "Two-Hit" Hypothesis for Liver Disease: Not all Pi*ZZ individuals develop liver disease; additional modifiers are required [13]:

• Second genetic hits (possibly SERPINA1 enhancer polymorphisms)
• Environmental factors (alcohol, obesity, viral hepatitis)
• Efficiency of autophagy pathways (genetically determined)
• Ability to activate the unfolded protein response
• This explains why only 10-15% of Pi*ZZ adults develop significant liver disease

Panniculitis Pathophysiology

AATD-associated panniculitis is rare but pathognomonic [14]:

• Neutrophil-mediated destruction of subcutaneous fat
• Unopposed protease activity in dermis and subcutis
• Presents as tender, red nodules often on trunk and proximal limbs
• Characteristically "suppurative" — may drain oily material
• May precede other manifestations of AATD
• Responds dramatically to AAT augmentation therapy

Summary: Dual Disease Mechanism

---

5. Clinical Presentation

Pulmonary Manifestations

AATD-related lung disease predominantly manifests as chronic obstructive pulmonary disease with specific characteristics distinguishing it from smoking-related COPD. [3,4]

Cardinal Features of AATD-Related COPD:

Symptoms by Stage:

Symptom Details:

Dyspnoea:

• Progressive exertional dyspnoea is the cardinal symptom
• Initially with strenuous activity, progressing to daily activities
• mMRC grade progression correlates with disease severity
• Disproportionate to smoking history should raise suspicion

Cough and Sputum:

• Chronic productive cough in 50-70%
• Mucoid sputum; becomes purulent during exacerbations
• May have wheezing suggesting reversible component

Wheeze and Chest Tightness:

• 25-30% have significant bronchodilator reversibility (> 12% and 200 mL)
• May be initially diagnosed as "asthma"
• Wheeze may be positional (worse supine)

Exacerbations:

• Increased frequency compared to non-AATD COPD
• Often triggered by viral upper respiratory infections
• Each exacerbation accelerates FEV1 decline
• Associated with increased mortality

Hepatic Manifestations

Liver disease affects approximately 10-15% of Pi*ZZ adults. [5,13]

Neonatal Presentation:

• 10-15% of Pi*ZZ infants develop neonatal cholestasis
• Presents at 1-3 months with conjugated hyperbilirubinaemia
• Hepatomegaly, acholic stools, dark urine
• 80-90% resolve spontaneously within first year
• 10-20% progress to cirrhosis in childhood requiring transplant

Adult Hepatic Disease:

Risk Factors for Adult Liver Disease:

• Male sex
• Age > 50 years
• Obesity
• Alcohol consumption
• Viral hepatitis co-infection
• Metabolic syndrome
• Genetic modifiers (incompletely understood)

Key Clinical Point: Liver disease may be the PRESENTING feature of AATD, particularly in never-smokers whose lungs are relatively preserved. Unexplained cirrhosis should prompt AATD testing.

Panniculitis

AATD-associated panniculitis is rare but virtually pathognomonic. [14]

Clinical Features:

• Tender, erythematous subcutaneous nodules
• Predominantly affects trunk and proximal limbs
• May have "suppurative" appearance with ulceration
• Can drain oily material (liquefactive necrosis of fat)
• Often preceded by trauma
• May precede pulmonary symptoms by years

Histology:

• Neutrophil-predominant septal and lobular panniculitis
• Liquefactive fat necrosis
• Distinctive "Swiss cheese" pattern

Therapeutic Response:

• Dramatic response to augmentation therapy
• May be indication for augmentation even without lung disease criteria

Rare Manifestations

Vasculitis:

• Granulomatosis with polyangiitis (GPA)-like presentation reported
• Positive anti-neutrophil cytoplasmic antibodies in some
• Unclear if true association or coincidental

Bronchiectasis:

• 15-25% of AATD patients have coexisting bronchiectasis
• May be consequence of recurrent infections
• Consider AATD in unexplained bronchiectasis with airflow obstruction

Heterozygote (Pi*MZ) Manifestations

The clinical significance of the Pi*MZ carrier state remains debated [15]:

---

6. Clinical Examination

Respiratory System Examination

General Inspection:

• Body habitus: Muscle wasting, weight loss in advanced disease
• Respiratory pattern: Pursed-lip breathing, prolonged expiration
• Use of accessory muscles: Sternocleidomastoid, scalene recruitment
• Central cyanosis: Late feature indicating hypoxaemia
• Finger clubbing: Not typical in uncomplicated AATD-COPD

Chest Examination:

Distinguishing Feature: In AATD, reduced breath sounds and hyper-resonance are typically more prominent at the lung BASES, whereas in smoking-related emphysema, upper zones are more affected.

Hepatic Examination

Inspection:

• Jaundice (late feature)
• Spider naevi (chronic liver disease)
• Palmar erythema
• Gynaecomastia (males)
• Ascites (decompensation)
• Caput medusae (rare)

Palpation:

• Hepatomegaly: May be present in early liver disease
• Splenomegaly: Suggests portal hypertension
• Ascites: Shifting dullness, fluid thrill

Important Note: Liver disease may be completely asymptomatic until advanced. Normal examination does not exclude significant liver involvement.

Skin Examination

Panniculitis Features:

• Tender subcutaneous nodules
• Erythematous overlying skin
• Location: trunk, proximal limbs, buttocks
• May show ulceration with oily discharge
• Often multiple lesions
• May show preceding trauma at site

Red Flags Requiring Immediate Investigation

[!CAUTION] Clinical Features That MUST Prompt AATD Testing:

• COPD/emphysema in patient less than 45 years old
• COPD in never-smoker or light smoker (less than 20 pack-years)
• Basilar-predominant emphysema on imaging
• Bronchiectasis with obstructive physiology
• Unexplained liver disease or cryptogenic cirrhosis
• Family history of emphysema or liver disease
• COPD patient with poor response to treatment
• Panniculitis (especially with oily discharge)

---

7. Investigations

Diagnostic Algorithm

                    SUSPECTED AATD
   (Young COPD, basal emphysema, non-smoker, family Hx)
                          |
                          ↓
┌───────────────────────────────────────────────────────┐
│            FIRST LINE: SERUM AAT LEVEL                │
│  Normal: 1.5-3.5 g/L (20-48 μM)                      │
│  Deficiency threshold: less than 1.0 g/L (11 μM)               │
├───────────────────────────────────────────────────────┤
│  ⚠️ Check during stable state (AAT is acute phase     │
│     reactant - elevated in inflammation)              │
└───────────────────────────────────────────────────────┘
                          |
         ┌────────────────┴───────────────┐
         |                                |
    NORMAL (> 1.5 g/L)              LOW (less than 1.0 g/L)
         |                                |
         ↓                                ↓
┌──────────────────┐    ┌──────────────────────────────┐
│  AATD unlikely   │    │  PROCEED TO GENOTYPING       │
│  (unless acute   │    │  Identifies Z, S, Null etc.  │
│   phase response)│    │  Gold standard for diagnosis │
└──────────────────┘    └──────────────────────────────┘
                                    |
         ┌──────────────────────────┴──────────────────┐
         |                  |                          |
    Pi*MM/MS            Pi*MZ                     Pi*ZZ/SZ
         |                  |                          |
         ↓                  ↓                          ↓
┌────────────────┐  ┌────────────────┐  ┌────────────────────────┐
│ Normal/carrier │  │ Heterozygote   │  │ CONFIRMED SEVERE AATD  │
│ Low risk       │  │ Counsel on     │  │                        │
│ Reassure       │  │ smoking risk   │  │ → Full management      │
│                │  │ Offer family   │  │   pathway              │
│                │  │ testing        │  │ → Family screening     │
└────────────────┘  └────────────────┘  │ → Augmentation if      │
                                        │   eligible             │
                                        └────────────────────────┘

Laboratory Investigations

Serum AAT Level:

Important Caveat: AAT is an acute phase reactant. Levels may be falsely elevated during:

• Acute infection/inflammation
• Pregnancy
• Oral contraceptive use
• Malignancy
• Repeat testing when stable if initial level borderline

Genotyping:

• Gold standard for definitive diagnosis
• PCR-based allele-specific methods for common alleles (M, S, Z)
• Full gene sequencing for rare variants when common alleles negative but AAT low
• Phenotyping (isoelectric focusing) now largely superseded by genotyping

Liver Function Tests:

Other Blood Tests:

Pulmonary Function Tests

Spirometry:

Lung Volumes:

Gas Transfer:

Severity Classification (GOLD):

Imaging

Chest X-Ray:

High-Resolution CT (HRCT):

The definitive imaging modality for characterising AATD-related lung disease.

Quantitative CT Densitometry:

• Used in research and to assess augmentation therapy response
• Measures lung density at full inspiration (% LAA-950)
• Correlates with emphysema severity
• The RAPID trial used CT densitometry as primary outcome [9]

Liver Imaging:

Liver Biopsy

Indicated when diagnosis of liver involvement is uncertain.

Pathognomonic Finding: Periodic acid-Schiff (PAS)-positive, diastase-resistant globules in hepatocyte cytoplasm.

Family Screening

All first-degree relatives of a Pi*ZZ patient should be offered testing:

• Parents: Will be at least Pi*MZ (carriers)
• Siblings: 25% chance of Pi*ZZ
• Children: 100% carriers if other parent PiMM; 50% PiZZ if other parent Pi*MZ

---

8. Classification and Staging

GOLD Classification for COPD Severity

AATD-related COPD is staged using the standard GOLD criteria [16]:

Spirometric Severity:

Combined Assessment (ABCD):

Liver Disease Staging

Child-Pugh Classification (for AATD cirrhosis):

Genotype Classification

---

9. Management

Management Algorithm

                    CONFIRMED AATD (Pi*ZZ/SZ)
                              |
                              ↓
┌──────────────────────────────────────────────────────────────┐
│             CORNERSTONE: SMOKING CESSATION                   │
│  Single most important intervention                          │
│  Transforms prognosis from 50-55 years to near-normal        │
│  Mandatory before augmentation therapy considered            │
└──────────────────────────────────────────────────────────────┘
                              |
         ┌────────────────────┼────────────────────┐
         ↓                    ↓                    ↓
┌────────────────┐  ┌────────────────┐  ┌────────────────────┐
│   PULMONARY    │  │    HEPATIC     │  │     LIFESTYLE      │
│   MANAGEMENT   │  │  SURVEILLANCE  │  │   MODIFICATIONS    │
└────────────────┘  └────────────────┘  └────────────────────┘
         |                    |                    |
         ↓                    ↓                    ↓
┌────────────────┐  ┌────────────────┐  ┌────────────────────┐
│ Standard COPD  │  │ Annual LFTs    │  │ Occupational       │
│ pharmacotherapy│  │ Ultrasound if  │  │ dust/fume          │
│ LAMA ± LABA    │  │ abnormal       │  │ avoidance          │
│ ± ICS          │  │ HCC screening  │  │ Vaccinations       │
│                │  │ if cirrhosis   │  │ Pulmonary rehab    │
└────────────────┘  └────────────────┘  └────────────────────┘
         |
         ↓
┌──────────────────────────────────────────────────────────────┐
│           CONSIDER AUGMENTATION THERAPY                      │
│  Criteria:                                                   │
│  - Severe deficiency (Pi*ZZ or equivalent)                  │
│  - Established COPD on spirometry                           │
│  - FEV1 35-65% predicted (optimal treatment window)         │
│  - Non-smoker or ex-smoker                                  │
│  - Already on optimal COPD therapy                          │
└──────────────────────────────────────────────────────────────┘
         |
         ↓
┌──────────────────────────────────────────────────────────────┐
│           TRANSPLANT CONSIDERATION                           │
│  Lung: FEV1 less than 25%, severe disability despite medical therapy  │
│  Liver: Decompensated cirrhosis (Child-Pugh B/C)            │
│  Combined: Rare; case-by-case                               │
└──────────────────────────────────────────────────────────────┘
         |
         ↓
┌──────────────────────────────────────────────────────────────┐
│           FAMILY CASCADE SCREENING                           │
│  First-degree relatives: parents, siblings, children         │
│  Serum AAT ± genotyping                                     │
│  Enables pre-symptomatic counselling                        │
└──────────────────────────────────────────────────────────────┘

Smoking Cessation

Critical Importance [4]:

Approach:

• Pharmacotherapy: NRT, varenicline, bupropion
• Behavioural support: Counselling, NHS Stop Smoking services
• Emphasise that AATD makes smoking uniquely dangerous
• Document smoking status at every visit
• Augmentation therapy generally not offered to current smokers

Lifestyle and Preventive Measures

Occupational Counselling:

• Avoid dusty, fume-laden environments
• Consider career counselling for at-risk individuals
• Respiratory protective equipment if exposure unavoidable

Vaccinations:

Pulmonary Rehabilitation:

• Improves exercise capacity, quality of life, dyspnoea
• Supervised exercise training, education, self-management
• Recommended for all symptomatic patients
• May reduce exacerbation frequency

Pharmacological Management of COPD

Standard GOLD guideline-directed therapy applies to AATD-COPD [16]:

Maintenance Therapy:

ICS Addition:

Inhaled Corticosteroid Options:

Rescue Therapy:

Exacerbation Management

Outpatient Management:

Hospital Management:

Augmentation Therapy

Mechanism: Intravenous infusion of pooled human plasma-derived AAT to raise serum and lung AAT levels above the protective threshold (11 μM). [9,17]

Available Products:

Eligibility Criteria [9,17]:

Evidence Base:

RAPID Trial (2015) [9]:

• Randomised, double-blind, placebo-controlled trial
• 180 patients with Pi*ZZ AATD and emphysema
• Primary outcome: Rate of lung density loss on CT
• Result: 34% reduction in rate of lung density decline with augmentation
• Led to approval of augmentation therapy in multiple jurisdictions

RAPID Extension [17]:

• 2-year open-label extension
• Patients who received early augmentation had sustained benefit
• Those who delayed treatment never "caught up"
• Supports early initiation in eligible patients

Limitations of Augmentation:

• Does not reverse established lung damage
• Modest effect on FEV1 decline (secondary outcome in RAPID)
• Lifelong, expensive treatment
• Requires weekly IV access
• Limited availability in some healthcare systems
• Not universally funded (UK: available via NHS; variable globally)

Practical Administration:

• Weekly IV infusion, typically 45-60 minutes
• Can be administered at home after training
• Self-administration or home healthcare provider
• Monitor for infusion reactions (rare)
• No routine monitoring of serum AAT levels required

Lung Transplantation

Indications:

• FEV1 less than 25% predicted
• Severe functional limitation despite maximal medical therapy
• BODE index ≥7
• Declining trajectory despite treatment
• Respiratory failure with LTOT dependence

Outcomes:

• 5-year survival approximately 50-60%
• Significant improvement in quality of life
• Does NOT cure the underlying deficiency (new lung unprotected)
• Consideration of augmentation post-transplant controversial

Contraindications (relative and absolute per transplant guidelines):

• Active smoking (absolute)
• Uncontrolled extrapulmonary infection
• Significant cardiac or renal dysfunction
• Recent malignancy
• Poor functional status/frailty

Liver Transplantation

Indications:

• Decompensated cirrhosis (Child-Pugh B or C)
• Hepatocellular carcinoma within Milan criteria
• MELD score indicating high mortality without transplant

Key Point: Liver transplantation is CURATIVE for AATD because the transplanted liver produces normal (Pi*M) AAT. This is the only treatment that addresses the underlying deficiency. [13]

Outcomes:

• 5-year survival > 85%
• Excellent outcomes compared to other aetiologies
• Normalises serum AAT levels
• Halts progression of lung disease (removes protease-antiprotease imbalance)
• Prior lung damage not reversed

Hepatic Surveillance

Recommendations for Pi*ZZ Adults:

Emerging Therapies

Gene Therapy and RNA Interference:

• Clinical trials underway using AAV vectors
• siRNA/antisense approaches to reduce Z-AAT production in liver
• May address both lung and liver disease

Small Molecule Chaperones:

• Compounds that stabilise Z-AAT and promote secretion
• Reduce polymer formation
• Early-phase clinical trials

Autophagy Enhancers:

• Carbamazepine and rapamycin analogues
• Enhance clearance of accumulated polymers
• Carbamazepine trials showed reduced liver fibrosis in mouse models

---

10. Complications

Pulmonary Complications

Hepatic Complications

Other Complications

Panniculitis:

• May be debilitating with chronic ulceration
• Responds to augmentation therapy
• May require wound care for ulcerated lesions

Psychosocial Impact:

• Chronic disease burden
• Genetic diagnosis implications for family
• Employment and insurance concerns
• Depression and anxiety common

---

11. Prognosis and Outcomes

Natural History

Pi*ZZ Individuals [4,6]:

Prognostic Factors

Favourable Prognosis:

• Never smoked
• Early diagnosis (before significant lung damage)
• Good baseline lung function
• Genotype other than PiZZ (e.g., PiSZ)
• Adherence to treatment and lifestyle modification
• Access to augmentation therapy
• No liver involvement

Poor Prognosis:

• Continued smoking
• Late diagnosis with established severe COPD
• FEV1 less than 30% predicted at diagnosis
• Frequent exacerbations (≥2/year)
• Hypoxaemic respiratory failure
• Concomitant liver cirrhosis
• Pulmonary hypertension
• Poor nutritional status

Treatment Outcomes

Smoking Cessation:

• Reduces FEV1 decline to near that of Pi*MM individuals
• Most impactful single intervention
• Can add decades to life expectancy

Augmentation Therapy [9,17]:

• 34% reduction in CT lung density decline (RAPID trial)
• Modest effect on FEV1 decline
• May reduce exacerbation frequency (observational data)
• Greatest benefit when started earlier in disease course

Lung Transplantation:

• 5-year survival: 50-60%
• Significant quality of life improvement
• Median survival post-transplant: 5-7 years

Liver Transplantation [13]:

• 5-year survival: > 85%
• Curative (normalises AAT production)
• Excellent long-term outcomes

Mortality Data

---

12. Prevention and Screening

Primary Prevention

For Known AATD (Pi*ZZ/SZ):

• Absolute smoking avoidance
• Occupational exposure minimisation
• Vaccination against respiratory pathogens
• Prompt treatment of respiratory infections

For Carriers (Pi*MZ):

• Smoking avoidance strongly advised
• General respiratory health measures
• No formal surveillance required

Screening Recommendations

Who Should Be Tested [1,6]:

Cascade Family Screening:

• All first-degree relatives should be offered testing
• Children of PiZZ patient: 100% carriers (if other parent PiMM)
• Siblings of PiZZ: 25% chance of PiZZ
• Prenatal/preimplantation testing available but rarely used

Newborn Screening

Current Status:

• Not routine in most countries
• Pilot programmes in some regions (Sweden historically)
• Potential benefits: early intervention, smoking prevention
• Concerns: psychosocial impact, uncertain clinical benefit in childhood

---

13. Evidence and Guidelines

Major Guidelines

ATS/ERS Statement on AATD (2003) [1]:

• Definitive joint statement on diagnosis and management
• Recommended one-time testing of all COPD patients
• Established augmentation therapy criteria
• Currently under revision with update expected

Alpha-1 Foundation Clinical Practice Guidelines (2016):

• US-focused comprehensive guidance
• Emphasis on augmentation therapy eligibility
• Liver disease monitoring recommendations

NICE COPD Guidelines (NG115, 2019) [16]:

• Recommends testing all COPD patients for AATD
• Integrates AATD management into COPD pathway

Landmark Trials

RAPID Trial (2015) [9]:

• Design: Randomised, double-blind, placebo-controlled
• Population: 180 patients with Pi*ZZ, FEV1 35-70%
• Intervention: IV AAT 60 mg/kg/week vs. placebo
• Duration: 24 months
• Primary outcome: CT lung density decline
• Result: 34% reduction in density decline (p=0.03)
• Impact: Established CT densitometry as valid endpoint; supported augmentation efficacy

RAPID Extension (2017) [17]:

• Open-label 24-month extension
• All patients received augmentation
• Early-start group maintained advantage
• Delayed-start never caught up
• Impact: Supports early treatment initiation

EXACTLE Trial (2009) [18]:

• Similar design to RAPID
• 77 patients
• Trend toward reduced FEV1 decline
• CT densitometry showed benefit
• Impact: Contributed to evidence base

Danish-Dutch Randomised Trial (1999) [19]:

• Early placebo-controlled trial
• 56 patients
• Showed trend toward reduced FEV1 decline
• Underpowered for definitive conclusions

Evidence Quality Summary

---

14. Exam-Focused Content

Common Exam Questions

For MRCP/FRACP (Medical Specialties):

1. "A 42-year-old non-smoker presents with progressive dyspnoea. CT shows basilar emphysema. What is your differential and approach?"

2. "What are the indications for augmentation therapy in AATD?"

3. "Describe the pathophysiology of liver disease in AATD. Why do null alleles not cause liver disease?"

4. "What is the inheritance pattern of AATD and what are the implications for family screening?"

5. "A patient with AATD asks about prognosis. What factors determine outcome?"

Viva Points

Opening Statement: "Alpha-1 antitrypsin deficiency is an autosomal codominant disorder caused by mutations in the SERPINA1 gene, characterised by reduced or dysfunctional AAT protein. The prototypic manifestation is early-onset panacinar emphysema due to unopposed neutrophil elastase activity, with additional liver disease risk from intrahepatic polymer accumulation in Z allele carriers."

Key Facts to Mention:

• Pi*ZZ genotype: 10-15% normal AAT levels
• Protective threshold: 35% (11 μM) — Pi*ZZ patients are below this
• Lung disease: panacinar, basilar emphysema
• Liver disease: 10-15% of Pi*ZZ adults (toxic gain-of-function)
• Smoking accelerates FEV1 decline 3-5 fold
• RAPID trial: 34% reduction in lung density decline with augmentation

Classification to Quote:

• GOLD staging for COPD
• Child-Pugh for liver disease
• Genotypes: M (normal), Z (severe), S (mild), Null (no protein)

Model Answers

Q: Describe your approach to a young patient with unexplained COPD

A: "I would approach this systematically. First, I would take a detailed history focusing on age of onset, smoking history quantified in pack-years, occupational exposures particularly dust and fumes, and family history of lung or liver disease. In examination, I would look for basilar predominant reduced breath sounds and signs of hyperinflation.

My investigations would include spirometry confirming obstructive physiology, and crucially a serum alpha-1 antitrypsin level with reflex genotyping. HRCT chest would characterise the emphysema pattern — panacinar basilar disease is classic for AATD versus centrilobular upper lobe in smoking-related disease.

If AATD is confirmed, management centres on absolute smoking cessation, which is the single most important intervention. I would optimise standard COPD therapy with LAMA/LABA combinations, ensure vaccinations are up to date, and refer for pulmonary rehabilitation.

For patients with severe deficiency, established COPD, and FEV1 35-65%, I would discuss augmentation therapy, which the RAPID trial showed reduces lung density decline by 34%. Finally, I would arrange family cascade screening and annual liver function surveillance given the risk of hepatic involvement."

Common Mistakes (What Fails Candidates)

• Forgetting that AATD can present with liver disease as the primary manifestation
• Not knowing that null alleles cause severe lung disease but NO liver disease
• Stating augmentation therapy "cures" or "reverses" emphysema
• Forgetting the FEV1 35-65% window for augmentation eligibility
• Not mentioning family screening
• Forgetting that liver transplant is curative (provides normal AAT)
• Missing the basilar distribution as the key imaging clue

---

15. Patient and Layperson Explanation

What is Alpha-1 Antitrypsin Deficiency?

Alpha-1 antitrypsin deficiency (often called "Alpha-1") is an inherited condition that runs in families. Your body normally makes a protein called alpha-1 antitrypsin (AAT) in the liver, which travels in your blood to your lungs. There, it protects your lungs from damage caused by immune cells doing their normal job of fighting infection.

If you have Alpha-1, your body either makes too little of this protective protein, or makes an abnormal version that doesn't work properly. Without enough protection, your lungs can become damaged over time, leading to a condition called emphysema, which makes breathing difficult.

Why Does It Matter?

If you have Alpha-1 and smoke, your risk of developing lung disease at a young age is very high. People with Alpha-1 who smoke often develop severe breathing problems in their 30s or 40s — decades earlier than typical smokers.

However, here's the important part: if you have Alpha-1 and never smoke, you may have a near-normal life expectancy. Knowing your diagnosis gives you the power to protect your lungs.

Some people with Alpha-1 also develop liver problems because the abnormal protein builds up in liver cells. This can lead to scarring of the liver (cirrhosis) in some people.

How Is It Treated?

1. Not Smoking (Most Important)

• If you smoke and have Alpha-1, stopping is the single most important thing you can do
• It can add decades to your life
• Even if you've already smoked, stopping now will slow down further damage

2. Inhalers and Lung Medicines

• Standard treatments for breathing problems help manage symptoms
• These are the same medicines used for other forms of COPD

3. Augmentation Therapy

• For some patients, weekly infusions of the missing AAT protein can help slow lung damage
• Not everyone qualifies — your doctor will discuss if this is right for you
• This is a lifelong treatment

4. Pulmonary Rehabilitation

• Exercise programmes help you stay as active as possible
• Teaches breathing techniques and energy conservation

5. Transplantation

• For severe lung disease, a lung transplant may be an option
• For severe liver disease, a liver transplant can actually cure the underlying condition

What Should Your Family Know?

Because Alpha-1 is inherited, your close relatives may also have it. We recommend that your parents, brothers, sisters, and children get tested. A simple blood test can tell them if they carry the gene.

Even if a family member has Alpha-1, knowing about it early — before any symptoms develop — means they can take steps to protect their health, especially avoiding smoking.

When to Seek Medical Help

Contact your doctor if you:

• Feel more short of breath than usual
• Develop a chest infection with increased cough or coloured sputum
• Notice swelling in your legs or tummy
• Have unexplained weight loss
• Develop yellowing of your eyes or skin

Key Messages

• Alpha-1 is lifelong but manageable
• Never smoking is the most powerful treatment
• Early diagnosis protects you and your family
• Regular check-ups help catch problems early
• Specialist centres exist to help manage your condition

Support Resources

• Alpha-1 UK Support Group: alpha1.org.uk
• Alpha-1 Foundation (US): alpha1.org
• British Lung Foundation: blf.org.uk
• Alpha-1 Global: alpha-1global.org

---

16. References

Primary Guidelines and Statements

1. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900. doi:10.1164/rccm.168.7.818. PMID: 14522813

2. Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency. N Engl J Med. 2020;382(15):1443-1455. doi:10.1056/NEJMra1910234. PMID: 32268028

Genetics and Molecular Biology

3. Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3):246-259. doi:10.1164/rccm.201108-1428CI. PMID: 21960536

4. Tanash HA, Nilsson PM, Nilsson JÅ, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax. 2008;63(12):1091-1095. doi:10.1136/thx.2008.095497. PMID: 18682522

5. Teckman JH, Mangalat N. Alpha-1 antitrypsin and liver disease: mechanisms of injury and novel interventions. Expert Rev Gastroenterol Hepatol. 2015;9(2):261-268. doi:10.1586/17474124.2014.943187. PMID: 25080028

Epidemiology

6. Stockley RA, Miravitlles M, Vogelmeier C; Alpha One International Registry (AIR). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis. 2013;8:149. doi:10.1186/1750-1172-8-149. PMID: 24063809

7. Blanco I, Bueno P, Diego I, et al. Alpha-1 antitrypsin PiZ gene frequency and PiZZ genotype numbers worldwide: an update. Int J Chron Obstruct Pulmon Dis. 2017;12:561-569. doi:10.2147/COPD.S125389. PMID: 28243081

8. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989-1994. doi:10.1378/chest.128.4.1989. PMID: 16236846

Clinical Trials

9. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360-368. doi:10.1016/S0140-6736(15)60860-1. PMID: 26026936

10. Holm KE, Borson S, Sandhaus RA, et al. Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. COPD. 2013;10(2):226-234. doi:10.3109/15412555.2012.719049. PMID: 23547635

Pathophysiology

11. Lomas DA. The selective advantage of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2006;173(10):1072-1077. doi:10.1164/rccm.200511-1797PP. PMID: 16439714

12. Laurell CB, Eriksson S. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132-140. doi:10.1080/00365516309051324. (Landmark paper)

13. Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. J Hepatol. 2018;69(6):1357-1364. doi:10.1016/j.jhep.2018.08.005. PMID: 30144557

14. Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S. New findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Arch Dermatol. 2009;145(10):1144-1150. doi:10.1001/archdermatol.2009.238. PMID: 19841402

Carrier Status

15. Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014;189(4):419-427. doi:10.1164/rccm.201311-1984OC. PMID: 24428606

Guidelines and Management

16. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16 s: diagnosis and management. NICE guideline [NG115]. 2019. Available from: https://www.nice.org.uk/guidance/ng115

17. McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51-60. doi:10.1016/S2213-2600(16)30430-1. PMID: 27916480

18. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345-1353. doi:10.1183/09031936.00159408. PMID: 19196813

19. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468-1472. doi:10.1164/ajrccm.160.5.9901055. PMID: 10556107

Additional Key References

20. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749-2757. doi:10.1056/NEJMcp0900449. PMID: 19553648

---

Last Reviewed: 2025-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This content does not replace professional medical advice, diagnosis, or treatment.